Background. Approximately 30% of fine needle aspiration biopsies of the thyroid have inconclusive results. We conducted a prospective trial to determine whether clinical and molecular markers could be used in combination to improve the accuracy of thyroid fine needle aspiration biopsy. Methods. Clinical, tumor genotyping for common somatic mutations (BRAF V600E, NRAS, KRAS, RET/ PTC1, RET/PTC3, and NTRK1), and the gene expression levels of 6 candidate diagnostic markers were analyzed by univariate and multivariate methods in 341 patients to determine whether they could distinguish reliably benign from malignant thyroid neoplasms, and a scoring model was derived. Results. By a multivariate analysis, fine needle aspiration biopsy cytology classification, the presence of a NRAS mutation, and the tissue inhibitor of metalloproteinase 1 expression level were associated jointly with malignancy. The overall accuracy of the scoring model, including these 3 variables, to distinguish benign from malignant thyroid tumors was 91%, including 67% for the indeterminate and 77% for the suspicious FNA subgroups. Conclusion. Fine needle aspiration biopsy cytology classification, the presence of NRAS mutation, and tissue inhibitor of metalloproteinase 1 messenger RNA expression levels in combination provide a greater diagnostic accuracy than fine needle aspiration biopsy cytology alone to allow selection of more definitive initial operative treatment. The sensitivity of the scoring model, however, was too low to avoid the need for diagnostic thyroidectomies for indeterminate fine needle aspiration biopsy findings. (Surgery 2010; 148:1170-7.) From the Endocrine Oncology Section, a Surgery Branch, National Cancer Institute, Bethesda, MD; and Departments of Pathology b and Surgery, c University of California, San Francisco, CA THE INCIDENCE OF THYROID CANCER has doubled over the past 3 decades, and an estimated 37,200 people were found to have thyroid cancer in 2009. 1 Fine needle aspiration biopsy (FNA) was adopted into widespread use in the 1970s to evaluate patients with thyroid nodules, and it has not only dramatically decreased the number of thyroidectomies for benign thyroid neoplasms, but also it has allowed for more definitive initial operative treatment of patients with malignant thyroid neoplasms. [2] [3] [4] FNA, however, may also be nondiagnostic or may demonstrate indeterminate or suspicious cytologic features in 20--30% of all biopsies. [3] [4] [5] [6] [7] The reported risk of malignancy in these FNA cytologic groups ranges from 5% to 75%. 5, 6 This limitation of FNA biopsy and cytologic examination is a result of indistinct cytologic features between benign and malignant tumors that commonly encompass follicular and Hurthle cell neoplasms, hyperplastic nodules, and follicular variant of papillary thyroid cancer. At least a diagnostic thyroidectomy is usually recommended in instances in which the FNA result is indeterminate or suspicious. Unfortunately, no preoperative clinical, imaging, or cytologic factors studied thus far can distinguish reliably which of those patients should undergo thyroidectomy. A recent National Cancer Institute (NCI) Thyroid Fine-Needle Aspiration State of the Science conference proposed a more expanded classification for FNA cytology that substratifies the indeterminate and suspicious FNA results into atypical follicular lesion of undetermined importance (risk of malignancy 5--10%), follicular or Hurthle cell neoplasm (risk of malignancy 15--25%), and suspicious for malignancy (risk of malignancy 50--75%). 7 The use of this classification varies among pathologists across various institutions, and diagnostic thyroidectomies are still necessary because the risk of malignancy is not negligible. 8 The development of adjunct diagnostic approaches to thyroid FNA biopsy has been an active area of thyroid cancer research. Activating somatic genetic alterations has been described in the signal transduction pathways involving tyrosine kinase receptors (RET/PTC and NTRK) and signaling proteins (RAS, BRAF), as well as in nuclear proteins (PAX8-PPARg) in thyroid cancer of follicular cell origin. [9] [10] [11] [12] [13] [14] [15] [16] Molecular testing for common somatic mutations in thyroid FNA biopsy has emerged as a promising approach because approximately two thirds of thyroid cancers of follicular cell origin have at least 1 of the common genetic alterations, which are absent in benign thyroid neoplasms (BRAF V600E point mutation, and RET/PTC and NTRK1 rearrangements). [11] [12] [13] [14] Our group has used pathway-specific complementary DNA (cDNA) array analysis previously to identify the candidate diagnostic and extent of disease markers in thyroid neoplasms that would be indeterminate or suspicious on FNA cytology. 17 From this analysis, 6 novel candidate diagnostic and extent-ofdisease markers were identified to have a high diagnostic accuracy. These genes included extracellular matrix protein 1 (ECM1); transmembrane protease, serine 4 (TMPRSS4); angiopoietin 2 (ANGPT2); tissue inhibitor of metalloproteinase 1 (TIMP1); ephrin-B2 (EFNB2); and epidermal growth factor receptor (EGFR). The goal of our current study was to determine whether demographics, clinical factors, and FNA cytology classification, in conjunction with somatic mutation analysis and expression level of 6 candidate markers, could improve the accuracy of thyroid FNA biopsy.
METHODS
Thyroid tissue and fine needle biopsy samples. Thyroid FNA samples, thyroid tissue, clinical data, and histopathology data were collected prospectively for 341 patients with 423 dominant thyroid nodules on a clinical protocol approved by the Committee on Human Research at the University of California, San Francisco. Demographic data collected included age, sex, ethnicity, family history of thyroid disease, and history of radiation exposure. The FNA samples were classified according to the NCI State of the Science recommendation. 7 The FNA biopsy samples were dispensed directly into TRIzol (Invitrogen, Carlsbad, CA), and total RNA was extracted immediately. In all, 174 samples were obtained at the time the patient underwent FNA biopsy of the dominant thyroid nodule in the outpatient clinic. One additional FNA pass was performed to obtain the sample for the study. The remaining 249 biopsies were performed with a 25-gauge needle at the time of thyroidectomy. All the intraoperative FNA biopsy samples were of the dominant nodule that was biopsied before the operation and had a cytologic diagnosis. The FNA biopsies performed at thyroidectomy were done with a single pass. The RNA amount obtained was similar between the intraoperative and clinic FNA samples as well as the RNA integrity number using the Agilent 2100 Bioanalyzer (Agilent, Foster City, CA). In all, 65 of these samples were classified as ''unknown'' FNA cytology diagnosis because the initial FNA biopsy was performed elsewhere, and the cytology was not reviewed at our institution to confirm the diagnosis. Tissue diagnoses were confirmed by permanent histology, which was used as the gold standard to determine accuracy.
Molecular analysis. Total RNA was extracted using the TRIzol reagent (Invitrogen). Total RNA (125 ng/mL) was reverse-transcribed using the RT script cDNA synthesis kit (USB Corp., Cleveland, OH). Real-time quantitative polymerase chain reaction (PCR) was used to measure messenger RNA (mRNA) expression levels relative to human b-glucuronidase (Gus) mRNA expression. Gene expression level = 2 --(Ct of gene of interest --Ct of Gus) 3 100%, where C t is the PCR cycle threshold. The PCR primers and probes for ANGPT2, ECM1, EGFR, EFNB2, TIMP1, and TMPRSS4 were purchased from Applied Biosystems (Foster City, CA). All PCR reactions were performed as described previously. 17 All quantitative PCR reactions were performed in triplicate and repeated at least twice.
FNA genotyping was performed for the following somatic mutations: BRAF V600E, NRAS (codons 12, 13 and 61), KRAS (codons 12, 13, and 61), RET/ PTC1, RET/PTC3, and NTRK1, as reported previously. 18 Statistical analysis. Chi-squared and Wilcoxon rank sum tests were used initially to screen for any possible association of categoric and continuous variables according to the histologic diagnosis Surgery Volume 148, Number 6 (benign versus malignant). A Cochran-Armitage test was used to determine the significance of the association between the FNA cytology classification and histologic diagnosis. Parameters significant in this initial univariate analysis (P < .05) were then analyzed using univariate and multiple logistic regression analyses to determine the degree to which disease status could be predicted based on the factors selected. The data were divided at random into 2 approximately equal sets: half for training the logistic scoring model and the other half for testing the model. Exploratory models were constructed from the training data set and then applied to the testing set to determine the accuracy of the model. This scoring model was then applied to the entire data set and the indeterminate and suspicious subgroups to obtain sensitivity, specificity, and overall accuracy (true positive and true negative results). All P values reported are 2-tailed and have not been adjusted for multiple comparisons. Statistical analysis was performed using commercially available software (SAS Inc., Cary, NC).
RESULTS
Patients. The demographic and clinical data are summarized in Table I . FNA biopsies were reviewed by our cytopathologist for 358 of 423 samples. Of the 181 biopsies with benign FNA cytology result, 135 did not undergo thyroidectomy (Fig) . On final histology, 165 nodules were benign and 123 were malignant. A cytologic examination of thyroid FNA biopsy samples showed that 51% were benign, 21% were malignant, 11% were atypical lesions, 12% were follicular or Hurthle cell neoplasms, and 4% were suspicious for malignancy. The average tumor size (greatest tumor diameter) on ultrasonography was 2.8 cm (range, 0.4--8.1). By univariate logistic regression analysis, age and FNA cytology classification were associated with classification into benign and malignant tumors (P # 0.03) but sex, family history, prior history of radiation, and tumor diameter were not.
Molecular analysis of thyroid FNA samples. Of 423 FNA samples, 24 BRAF V600E mutations, 7 KRAS mutations, 21 NRAS mutations, 4 PAX8-PPARg rearrangements, 3 RET/PTC1, and 2 RET/ PTC3 rearrangements were detected. In all, 17 of 165 (10.3%) benign thyroid tumors had a somatic mutation compared with 32 of 123 (26%) malignant neoplasms (P < .05). NTRK1 rearrangement was not detected in any of the FNA samples. On univariate analysis, ANGPT2, EGFR, EFNB2, TIMP1, and TMPRSS4 were expressed differentially between benign and malignant tumors (P # .0001).
Scoring model. The variables associated significantly with malignancy on univariate analysis were included in a multiple logistic regression analysis. FNA cytology classification (P < .0001), presence of NRAS mutation (P = .016), and TIMP1 expression level (P = .067) were associated jointly with malignancy in the multiple logistic model analysis. A scoring model was created using these variables in a training set and then applied to a testing set. In the training set, the model led to the following rule for distinguishing between benign and malignant tumors: Calculate 1.532 3 FNA cytology classification + 0.00137 3 TIMP1 normalized expression + 1.8816 (if NRAS mutation present). A total score greater than 4.81 would predict a tumor to be malignant, and a score less than 4.81 was considered benign. In the testing set, this rule had 85% accuracy, 89% specificity, and 77% sensitivity. When this model was reapplied to the entire data set, the overall accuracy to distinguish benign from malignant thyroid tumors was 91%, with a specificity of 97% and sensitivity of 76%. In the FNA biopsies of the atypical follicular or Hurthle cell lesions, 15 of 41 (37%) nodules were malignant (Table II) . The scoring model, when applied to this subgroup, was 61% accurate, with a specificity of 81% and sensitivity of 27% (P < .001). In the subgroup of indeterminate neoplasms, 31.8% were malignant. The scoring model was 61% accurate, with 100% specificity and 14% sensitivity for this FNA subgroup (P < .001). In the suspicious FNA group, 77% were malignant, of which 100% were detected by the scoring model (P < .001). The overall accuracy of the scoring model for this group was 77%.
DISCUSSION
In this study, we analyzed demographic, clinical, and molecular markers in patients with thyroid neoplasms to determine whether any of these variables could be used to improve the diagnostic accuracy of thyroid FNA biopsy and cytologic examination alone. We used univariate and multivariate analyses to develop a scoring model that could classify benign and malignant thyroid neoplasms based on a combination of variables. A scoring model using normalized TIMP1 mRNA expression levels, FNA cytology, and presence of NRAS mutation was the most accurate, classifying correctly 91% of all biopsy samples as benign or malignant neoplasms. The application of this model to a subgroup of patients with either an atypical lesion or indeterminate neoplasm FNA cytology demonstrated that it was 61% accurate but had a low sensitivity. In the subgroup of FNA biopsies that were suspicious for malignancy, the model identified correctly 100% of patients with a malignancy and was 77% accurate with a false positive rate of 23%.
Since its introduction, FNA has decreased the number of diagnostic thyroidectomies performed for benign nodules and increased the number of patients who received complete initial operative treatment for malignant thyroid neoplasms. Currently, FNA is the most reliable, widely used, and most cost-effective initial test to distinguish between a benign and malignant thyroid nodule; however, it is inconclusive for certain histologic subtypes of neoplasms, which result commonly in biopsies that are interpreted as indeterminate or suspicious for malignancy, thus requiring the need for a thyroidectomy to obtain a definitive histologic diagnosis. [3] [4] [5] [6] Numerous studies have evaluated the potential diagnostic markers to improve the accuracy of FNA, but few have had clinical utility in tumors that are indeterminate or suspicious on FNA cytology. [9] [10] [11] [12] [13] [14] [15] Nikiforov et al 19 tested 470 consecutive FNA Surgery Volume 148, Number 6 samples prospectively from 371 patients for a panel of mutations, including BRAF, RAS, RET/PTC, and PAX8-PPARg, and they found that the presence of any mutation was a strong predictor of cancer. Additionally, they found molecular testing to be 100% accurate in the lowest risk subgroup---follicular lesion of indeterminate significance. Sapio et al 20 confirmed a diagnosis in 25% of 16 FNA biopsies suspicious for papillary thyroid cancer by mutation analysis for RET/PTC1, RET/PTC3, BRAF, and NTRK. Our results also show a significantly greater rate of somatic mutations in malignant thyroid nodules but with low sensitivity. Thus, somatic mutation analysis is likely to be most useful when positive to allow for more definitive initial operations, rather than to avoid the need for a diagnostic thyroidectomy when FNA biopsy shows results indeterminate or suspicious for malignancy. 21 Previously, we had identified 6 novel diagnostic markers for thyroid neoplasms that would be indeterminate or suspicious on FNA biopsy in 31 thyroid FNA biopsy samples. 17 In this study, demographic and clinical data, as well as tumor FNA genotype for common somatic mutations (BRAF V600E, NRAS, KRAS, RET/PTC1, RET/PTC3, and NTRK1), and the previously identified 6 candidate gene expression levels were analyzed in 423 FNA biopsy samples to determine whether they could distinguish benign from malignant thyroid tumors. Five of the 6 candidate genes (ANGPT2, EGFR, EFNB2, TIMP1, and TMPRSS4) were able to differentiate (P < .05) between benign and malignant thyroid tumors when evaluated in 423 FNA biopsy samples.
In contrast to our prior studies, TIMP1 expression level was the only independent diagnostic marker in addition to presence of a NRAS mutation that added to the accuracy of FNA cytology. This observation is likely a result of having a much greater sample size in the current study, which allowed for the separation of candidate gene expression patterns in benign and malignant *All the tumors were conventional papillary thyroid cancer and 1.5 cm or less in greatest diameter but in the dominant nodule that was biopsied. Thus, the cytopathologic diagnosis was a false-negative interpretation. These patients had a thyroidectomy either because of increased tumor size on follow-up ultrasound or suspicious ultrasound features.
samples encompassing a much broader histology of thyroid tumors. An acceptable scoring model derived from a training set and applied to an independent testing cohort had an excellent diagnostic accuracy of 91%, with a specificity of 97% when applied to the entire cohort; however, the sensitivity of this model for the entire cohort was only 76%. The accuracy dropped to 61% for atypical lesions or indeterminate FNA samples. In the FNA subgroup of atypical follicular or Hurthle cell lesions, the specificity was 81%, with a low sensitivity of 27%. This finding suggests that this model would not be helpful to determine the need and extent of thyroidectomy for an atypical lesion or indeterminate neoplasm FNA result. In the subgroup of patients with indeterminate FNA results, the scoring model had a specificity of 100% and a sensitivity of 14%. In the FNA subgroup suspicious for malignancy, the model was 77% accurate with a 100% sensitivity but a 0% specificity, suggesting that this model might be useful to determine the extent of initial thyroidectomy for an indeterminate neoplasm or an FNA suspicious for malignancy; however, the sample size in each group was relatively small. We recognize that management decisions in patients with inconclusive thyroid FNA biopsy may be variable because there are no clearly established thresholds when a patient and surgeon would elect to not undergo or perform a diagnostic thyroidectomy or to determine the extent of thyroidectomy needed. To our knowledge, ours is one of the largest comprehensive studies that incorporated multiple clinical factors with FNA genotyping for known somatic mutations in addition to 6 candidate markers identified previously by cDNA array analysis to create a scoring model to improve the accuracy of FNA. Although this model had a high diagnostic accuracy, we do not believe the sensitivity was great enough to avoid the need for a diagnostic thyroidectomy in patients with indeterminate FNA results. In contrast, in patients with suspicious FNA results, the model identified correctly 100% of patients with cancer and may be used to guide initial operative treatment. The main limitations of this study were the relatively smaller sample size of patients in the atypical, indeterminate, and suspicious FNA subgroups for us to make strong clinical management recommendations based on our result. Additionally, some variability may exist with FNA cytologic classification according to the NCI State of the Science conference, which may not be interpreted uniformly as such at other center or by other cytopathologists.
In conclusion, this study introduces a novel scoring model incorporating TIMP1 expression and presence of NRAS mutation to improve the diagnostic accuracy of FNA or at least to quantitate the preoperative risk of malignancy more accurately. The classification of FNA cytology according to the NCI guidelines, presence of an NRAS mutation, and TIMP1 mRNA expression levels in combination might better predict the risk of malignancy and thus allow the selection of more definitive initial operative treatment. We believe prospective clinical trials to validate many of the proposed markers identified for thyroid cancers are needed to determine their ultimate clinical utility. DISCUSSION Dr Christopher R. McHenry (Cleveland, OH): I have one question. So, as I understand it, the goal here was to use your combination of clinical factors, fine needle aspiration cytology, and candidate diagnostic markers to help identify those patients who would benefit from surgical intervention.
My question is, why did you choose to include the patients that had a prior history of radiation exposure in your data set? I guess my sense would be that would be a patient population on which you would operate because of the high incidence of cancer. And I wondered if you excluded those patients from your data set, would that have altered your results?
Dr Aarti Mathur (Bethesda, MD): Yes, our goal was to use a combination of clinical factors, fine needle aspiration cytology, and candidate diagnostic markers to identify those patients who would benefit from an initial definitive procedure and to reduce the number of diagnostic thyroidectomies that are performed. We chose a study population representative of a typical practice that would naturally include some patients with a prior history of radiation. Only 36 patients of the 423 had received prior radiation accounting for a very small percentage. However, we have not looked at the data set after excluding those patients. It is a very good point and we will certainly take a look at that.
Dr Sally E. Carty (Pittsburgh, PA): You evaluated a heterogenous population. When you are assessing FNA accuracy, there is only two ways to say whether benign cytology is truly benign. One is to operate on all comers, and the other is to have long-term nonoperative follow-up.
What was your length of follow-up? How did you exclude the fact that you missed cancer with your first analysis? And how do you think your experimental design addresses the issue of the heterogenous population that you describe?
Dr Aarti Mathur (Bethesda, MD): Our median followup was 2 years. I agree, we need to follow patients with a benign nodule that we did not operate on for a longer period of time as the false positive rate of a benign FNA biopsy has been reported to be as high as 13%. However, those patients with a benign FNA biopsy that were operated on had another indication for an operation. Those patients were included in the final analysis to develop the scoring model.
To speak to the heterogeneity of our patient population, again, it is just representative of what we would normally see in a practice.
Dr Geeta Lal (Iowa City, IA): Thank you for your presentation. It really speaks to the value of prospectively evaluating all the markers that we see presented. My question is the following: You had a training set and then a validation set, and you showed data on ECM1, which your group and we have looked at that marker, too, as a utility and diagnostic prediction for malignancy. Your slide there showed that ECM1 expression was no different in the benign versus malignant group.
When we looked at the data, the Hurthle cell lesions or Hurthle cell cancers really fell out. There was no difference. The group where ECM1 had the most utility was in follicular cancers and follicular variant of papillary cancers. So, I wonder if putting even though the numbers might be small, anaplastic, medullary, Hurthle cell lesions, all of that changed the sensitivity that you yourself have reported in your previous studies on ECM1? Could you comment on that?
Dr Aarti Mathur (Bethesda, MD): We actually did not stratify out the different thyroid cancer histologies to evaluate gene expression levels among them as the sample size was small for each group except the papillary cancer cases, but we certainly can do that.
Dr Martha A. Zeiger (Baltimore, MD): I congratulate you on a very nicely presented paper, and I also congratulate you on the detail in which you actually evaluated your findings.
I have a comment that I would like you to comment on. And I think it is important for us to keep in mind that what we are trying to solve is the indeterminate and suspicious fine needle aspiration biopsy. Many, many studies, including my own, tend to look at tumors where we already can diagnose them. So, looking at tumors where we have a diagnosis of malignancy and putting them into this model is not particularly useful. And I think it was very nice that you pulled out the indeterminate lesions. I think once you do that, it then becomes apparent that fine needle aspiration biopsy is probably still the most accurate thing that we have.
We have a nice predictive model, based on the nomenclature that came out of NIH. And that is what we really need to impact, and that is what we need to target, not overall tumors. Because we are already nearly 100% sensitive in picking up malignancy, we rarely miss it. I wondered if you could just further comment on that?
Dr Aarti Mathur (Bethesda, MD): Because FNA cytology is nearly 100% correct when interpreted to be malignant, we chose to include those patients to evaluate our other variables. We incorporated the benign and malignant FNA diagnoses, in addition to the final histology, only to help us create the scoring model. By incorporating tumors that can already be diagnosed, we were hoping to develop a model that would improve on the existing classification of FNA biopsies with respect to risk of malignancy. However, our scoring model provided marginal benefit for the small group of patients that had an indeterminate or suspicious lesion.
Dr Lawrence Kim (Little Rock, AR): You stated that the vast majority of your patients had a single nodule. Did you actually mean that only a single nodule was biopsied? Because in my experience, the vast majority of patients with a nodule actually have more than one nodule.
Dr Aarti Mathur (Bethesda, MD): The vast majority had a single dominant palpable or sonographically detected nodule, and those were the ones biopsied according to common established guidelines and thus reported as a single nodule. We did have some patients with more than 1 dominant nodule detected, in which case multiple nodules were biopsied if they met the established guidelines of the American Thyroid Association.
Dr Douglas Evans (Milwaukee, WI): That was a great presentation. I just want to understand a little bit about your methodology for those of us who struggle with translational research. So, if the FNA was not of adequate quality, in the operating room you took the thyroid out, and then FNA biopsied the specimen?
Dr Aarti Mathur (Bethesda, MD): The FNA was performed prior to making the skin incision.
Dr Douglas Evans (Milwaukee, WI): Did you have to have patient consent for that?
Dr Aarti Mathur (Bethesda, MD): Yes, this was done on an approved protocol.
Dr Douglas Evans (Milwaukee, WI): So how many patients refused consent, then? Just in thinking about this, I would have just taken the thyroid out first. You probably then could have had a waiver of consent.
And my next question would be, did you then use those patients as internal controls, because you then would know the accuracy of whether the tissue actually came from the nodule versus the preoperative FNAs, where that probably was not clear?
Dr Aarti Mathur (Bethesda, MD): That is a great question. I will let Dr. Kebebew answer.
Dr Electron Kebebew (Bethesda, MD): First, we had done a pilot ex vivo FNA study to demonstrate that we could perform the molecular analysis. The patients reported in this study had percutaneous FNA biopsy. The nucleic acid yield was similar to the ex vivo pilot study. We had a total of, I think, 23 patients of more than 700 plus patients who refused to participate in the study.
Dr Douglas Evans (Milwaukee, WI): So, did you then compare did you have any patients, any, if you will, nodules, that could serve as your own controls, ie, they were FNA biopsied by a surgeon, an endocrinologist, or a pathologist, and then you did your ex vivo FNA where you knew the needle was actually in the nodule. Did you compare those 2 profiles?
Dr Electron Kebebew (Bethesda, MD): We had done that as a pilot study between the cytopathologists', and the yield of FNA biopsy and intraoperative biopsy was also similar; the genome wide expression profiles also clustered together for the same samples obtained from the same patient thyroid nodule. However, it is impossible to say the results in our study are not affected by sampling error, which is inherent in thyroid FNA biopsy.
